Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian National Association for the study of the liver, endocrine society of India, Indian college of cardiology and Indian society of gastroenterology

Journal of Clinical and Experimental Hepatology

Volumn 5, Issue 1, 2015, Pages 51-68

  Duseja, Ajay ^a   Singh, Shivaram P ^b   Saraswat, Vivek A ^c   Acharya, Subrat K ^d   Chawla, Yogesh K ^a   Chowdhury, Subhankar ^e   Dhiman, Radha K ^a   Jayakumar, Rohinivilasam V ^f   Madan, Kaushal ^g   Misra, Sri P ^h   Mishra, Hrudananda ^b   Modi, Sunil K ⁱ   Muruganathan, Arumugam ^j   Saboo, Banshi ^k   Sahay, Rakesh ^l   Upadhyay, Rajesh ^m  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b SCB MEDICAL COLLEGE   (India)

^c SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^e INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^f AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

^g Medanta Institute of Digestive and Hepatobiliary Sciences   (India)

^h MLN MEDICAL COLLEGE   (India)

ⁱ INDRAPRASTHA APOLLO HOSPITAL   (India)

^j Tamilnadu Dr MGR Medical University   (India)

^k Dia Care Hormone Clinic   (India)

^l OSMANIA MEDICAL COLLEGE   (India)

^m Max Super Speciality Hospital   (India)

more..

Author keywords

Cryptogenic cirrhosis; Insulin resistance; NAFLD; NASH; Nonalcoholic steatohepatitis

Indexed keywords

ALCOHOL; ALPHA TOCOPHEROL; ATORVASTATIN; BETAINE; GLITAZONE DERIVATIVE; LOSARTAN; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; S ADENOSYLMETHIONINE; URSODEOXYCHOLIC ACID;

AEROBIC EXERCISE; ALCOHOL CONSUMPTION; ASIAN; BARIATRIC SURGERY; BLOOD SAMPLING; CARDIOLOGIST; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ECHOGRAPHY; ENDOCRINOLOGIST; ETHNIC DIFFERENCE; EXERCISE; GENE MUTATION; HUMAN; HYPERTENSION; INCIDENCE; INDIA; INDIAN; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LOW CALORY DIET; LOW CARBOHYDRATE DIET; LOW FAT DIET; MEDICAL SOCIETY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC STEATOHEPATITIS RELATED CIRRHOSIS; NONCIRRHOTIC NONALCOHOLIC FATTY LIVER DISEASE; OBESITY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; RISK FACTOR; WEIGHT REDUCTION;

EID: 84928696497     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2015.02.006     Document Type: Review

References (109)

1. Anjana R.M., Pradeepa R., Deepa M., et al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdiaDIABetes (ICMR-INDIAB) study. Diabetologia 2011, 54:3022-3027.
2. International Diabetes Federation Diabetes Atlas 2011, International Diabetes Federation, Brussels, Belgium. 5th ed.
3. Gupta R. Trends in hypertension epidemiology in India. JHum Hypertens 2004, 18:73-78.
4. Mohan V., Seedat Y.K., Pradeepa R. The rising burden of diabetes and hypertension in southeast asian and african regions: need for effective strategies for prevention and control in primary health care settings. Int J Hypertens 2013, 2013:409083.
5. Misra A., Shrivastava U. Obesity and dyslipidemia in South Asians. Nutrients 2013, 5:2708-2733.
6. Misra A., Vikram N.K. Insulin resistance syndrome (metabolic syndrome) and obesity in Asian Indians: evidence and implications. Nutrition 2004, 20:482-491.
7. Wasir J.S., Misra A. The metabolic syndrome in Asian-Indians: impact of nutritional and socio-economic transition in India. Metab Syndr Relat Disord 2004, 2:14-23.
8. Misra A., Misra R. Asian Indians and insulin resistance syndrome: global perspective. Metab Syndr Relat Disord 2003, 1:277-283.
9. Misra A., Khurana L. The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. Metab Syndr Relat Disord 2009, 7:497-514.
10. Luthra A., Nigam P., Misra A. Metabolic correlates of non-alcoholic fatty liver disease and management issues: a perspective for Asian Indians. Diabetes Metab Syndr Res Rev 2007, 1:279-285.
11. Bajaj S., Nigam P., Luthra A., et al. Acase-control study on insulin resistance, metabolic co-variates & prediction score in non-alcoholic fatty liver disease. Indian J Med Res 2009, 129:285-292.
12. Petersen K.F., Dufour S., Feng J., et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A 2006, 103:18273-18277.
13. Petersen K.F., Dufour S., Hariri A., et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. NEngl J Med 2010, 362:1082-1089.
14. Duseja A., Aggarwal R. APOC3 and PNPLA3 in non-alcoholic fatty liver disease: need to clear the air. JGastroenterol Hepatol 2012, 27:848-851.
15. Duseja A. Nonalcoholic fatty liver disease in India - is it different?. Trop Gastroenterol 2006, 27:142-146.
16. Duseja A., Das A., Das R., et al. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig Dis Sci 2007, 52:2368-2374.
17. Duseja A., Das A., Dhiman R.K., et al. Indian patients with nonalcoholic fatty liver disease presenting with raised transaminases are different at presentation. World J Gastroenterol 2007, 13:649-650.
18. Duseja A. Nonalcoholic fatty liver disease in India - a lot done, yet more required!. Indian J Gastroenterol 2010, 29:217-225.
19. Chitturi S., Farrell G.C., George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock?. JGastroenterol Hepatol 2004, 19:368-374.
20. Zhou Y.J., Li Y.Y., Nie Y.Q., et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007, 13:6419-6424.
21. Li Y., Xu C., Yu C., et al. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. JHepatol 2009, 50:1029-1034.
22. Akahoshi M., Amasaki Y., Soda M., et al. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertens Res 2001, 24:337-343.
23. Lai S.W., Ng K.C. Which anthropometric indices best predict metabolic disorders in Taiwan?. South Med J 2004, 97:578-582.
24. Lee K., Sung J.A., Kim J.S., Park T.J. The roles of obesity and gender on the relationship between metabolic risk factors and non-alcoholic fatty liver disease in Koreans. Diabetes Metab Res Rev 2009, 25:150-155.
25. Singh S.P., Nayak S., Swain M., et al. Prevalence of non-alcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. Trop Gastroenterol 2004, 25:76-79.
26. Amarapurkar D., Kamani P., Patel N., et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 2007, 6:161-163.
27. Mohan V., Farooq S., Deepa M., et al. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract 2009, 84:84-91.
28. Das K., Das K., Mukherjee P.S., et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010, 51:1593-1602.
29. Duseja A., Bhansali A., Bhadada S., et al. Nonalcoholic fatty liver disease in patients with recent onset type 2 diabetes mellitus (abstract). JGastroenterol Hepatol 2004, 19(suppl l):A402.
30. Gupte P., Amarapurkar D., Agal S. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. JGastroenterol Hepatol 2004, 19:854-858.
31. Duseja A., Chawla Y. Nonalcoholic fatty liver disease in India - how much? How soon?. Trop Gastroenterol 2005, 26:1-3.
32. Wong V.W., Vergniol J., Wong G.L., et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010, 51:454-462.
33. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
34. Kleiner D.E., Brunt E.M., Van Natta M., et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
35. Clark J.M., Diehl A.M. Nonalcoholic fatty liver disease: an under-recognized cause of cryptogenic cirrhosis. JAMA 2003, 289:3000-3004.
36. Caldwell S.H., Oelsner D.H., Lezzoni J.C., et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999, 29:664-669.
37. Amarapurkar D., Das H.S. Chronic liver disease in diabetes mellitus. Trop Gastroenterol 2002, 23:3-5.
38. Duseja A., Sharma B., Kumar A., et al. Nonalcoholic fatty liver in a developing country is responsible for significant liver disease. Hepatology 2010, 52:2248-2249.
39. Nayak N.C., Vasdev N., Saigal S., Soin A.S. End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program. Hum Pathol 2010, 41:425-430.
40. Marrero J.A., Fontana R.J., Su G.L., et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36:1349-1354.
41. Das D., Chattopadhyay D., Aslam T., et al. NAFLD and the changing face of hepatocellular cancer (HCC) [Abstract]. Gut 2011, 60(suppl 1):A243.
42. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140.
43. Abe H., Yoshizawa K., Kitahara T., et al. Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. JGastroenterol 2008, 43:967-974.
44. Oh K.C., Park S.H., Park J.C., et al. Is the prevalence of cryptogenic hepatocellular carcinoma increasing in Korea?. Korean J Gastroenterol 2005, 45:45-51.
45. Song H.Y., Lee H.K., Lee J.S., et al. Risk factors of cryptogenic hepatocellular carcinoma in patients with low body mass index or without metabolic syndrome. Korean J Intern Med 2012, 27:47-52.
46. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. NEngl J Med 2010, 363:1341-1350.
47. McKimmie R.L., Daniel K.R., Carr J.J., et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 2008, 103:3029-3035.
48. Volzke H., Robinson D.M., Kleine V., et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastronterol 2005, 11:1848-1853.
49. Brea A., Mosquera D., Martín E., et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Biol 2005, 25:1045-1050.
50. Guleria A., Duseja A., Kalra N., et al. Patients with non-alcoholic fatty liver disease (NAFLD) have an increased risk of atherosclerosis and cardiovascular disease. Trop Gastroenterol 2013, 34:74-82.
51. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
52. Shibata M., Kihara Y., Taguchi M., et al. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007, 30:2940-2944.
53. Reaven G. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
54. DeFronzo R.A., Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194.
55. World Health Organization Department of Non-communicable Disease Surveillance Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation 1999, World Health Organization, Geneva.
56. Balkau B., Charles M.A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999, 16:442-443.
57. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. National Cholesterol Education Program (NCEP) Expert Panel On Detection, Evaluation, And Treatment Of High Blood Cholesterol in Adults (Adult Treatment Panel III).
58. American Diabetes Association Standards of medical care in Diabetes-2014. Diabetes Care 2014, 37(suppl 1):S14-S80.
59. 2) Asian Indians with normal waist circumference have high cardiovascular risk. Nutrition 2003, 19:503-509.
60. Misra A., Misra R., Wijesuriya M., Banerjee D. The metabolic syndrome in South Asians: continuing escalation & possible solutions. Indian J Med Res 2007, 125:345-354.
61. Almeda-Valdés P., Cuevas-Ramos D., Aguilar-Salinas C.A. Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol 2009, 8:S18-S24.
62. Paschos P., Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009, 13:9-19.
63. Bugianesi E., McCullough A., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42:987-1000.
64. Athyros V.G., Bouloukos V.I., Pehlivanidis A.N., et al. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab 2005, 7:397-405.
65. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
66. Duseja A., Thumburu K.K., Das A., et al. Insulin tolerance test is comparable to homeostasis model assessment for insulin resistance in patients with nonalcoholic fatty liver disease. Indian J Gastroenterol 2007, 26:170-173.
67. Madan K., Batra Y., Gupta S.D., et al. Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians. World J Gastroenterol 2006, 12:3400-3405.
68. Bhat G., Baba C.S., Pandey A., et al. Life style modification improves insulin resistance and liver histology in patients with non-alcoholic fatty liver disease. World J Hepatol 2012, 4:209-217.
69. Hernaez R., Lazo M., Bonekamp S., et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011, 54:1082-1090.
70. de Ledinghen V., Vergniol J., Foucher J., et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012, 32:911-918.
71. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
72. Singh D.K., Rastogi A., Sakhuja P., Gondal R., Sarin S.K. Comparison of clinical, biochemical and histological features of alcoholic steatohepatitis and non-alcoholic steatohepatitis in Asian Indian patients. Indian J Pathol Microbiol 2010 Jul-Sep, 53:408-413.
73. Singh D.K., Sakhuja P., Malhotra V., Gondal R., Sarin S.K. Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis. Dig Dis Sci 2008 Jul, 53:1967-1976.
74. Das S., Singh S.P., Parida P.K., Mallik R.N. Non-alcoholic fatty liver disease in subjects with type 2 diabetes mellitus and non-diabetics with special reference to insulin resistance and hepatic histopathological changes. Diabetes Metab Syndr: Clin Res Rev 2010, 4:226-229.
75. Palmer M., Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990, 99:1408-1413.
76. Ueno T., Sugawara H., Sujaku K., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. JHepatol 1997, 27:103-107.
77. Samaha F.F., Iqbal N., Seshadri P., et al. Alow-carbohydrate as compared with a low-fat diet in severe obesity. NEngl J Med 2003, 348:2074-2081.
78. Huang M.A., Greenson J.K., Chao C., et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005, 100:1072-1081.
79. Dansinger M.L., Gleason J.A., Griffith J.L., et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005, 293:43-53.
80. Marchesini G., Brizi M., Bianchi G., et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358:893-894.
81. Uygun A., Kadayifci A., Isik A.T., et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004, 19:537-544.
82. Nair S., Diehl A.M., Wiseman M., et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004, 20:23-28.
83. Bugianesi E., Gentilcore E., Manini R., et al. Arandomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:1082-1090.
84. Haukeland J.W., Konopski Z., Eggesbø H.B., et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009, 44:853-860.
85. Duseja A., Das A., Dhiman R.K., et al. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 2007, 6:222-226.
86. Promrat K., Lutchman G., Uwaifo G.I., et al. Apilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39:188-196.
87. Belfort R., Harrison S.A., Brown K., et al. Aplacebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. NEngl J Med 2006, 355:2297-2307.
88. Sanyal A.J., Mofrad P.S., Contos M.J., et al. Apilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004, 2:1107-1115.
89. Sharma B.C., Kumar A., Garg V., et al. Arandomized controlled trial comparing efficacy of pentoxifylline and pioglitazone on metabolic factors and liver histology in patients with non-alcoholic steatohepatitis. JClin Exp Hepatol 2012, 2:333-337.
90. Hasegawa T., Yoneda M., Nakamura K., et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Ailment Pharmacol Ther 2001, 15:1667-1672.
91. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. NEngl J Med 2010, 362:1675-1685. NASH CRN.
92. Lindor K.D., Kowdley K.V., Heathcote E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39:770-778.
93. Laurin J., Lindor K.D., Crippin J.S., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996, 23:1464-1467.
94. Singh S.P., Das H.S., Panda C.R., et al. Apilot study of high dose of ursodeoxycolic acid (UDCA) in the treatment of nonalcoholic steatohepatitis [NASH]. Indian J Gastroenterol 2007, 26(suppl 2):A90.
95. Ratziu V., de Ledinghen V., Oberti F., et al. Arandomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. JHepatol 2011, 54:1011-1019. FRESGUN.
96. Abdelmalek M.F., Sanderson S.O., Angulo P., et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009, 50:1818-1826.
97. Yokohama S., Yoneda M., Haneda M. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222-1225.
98. Adams L.A., Zeine C.O., Angulo P., Lindol K.D. Apilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99:2365-2368.
99. Buranawui W., Thung-u-thaisri P., Pramoolsinsap C., et al. Pentoxifylline for treatment of non-alcoholic fatty liver disease (NAFLD): a randomized, placebo-controlled study [Abstract s2161]. Gastroenterology 2006, A330.
100. Satapathy S.K., Sakhuja P., Malhotra V., et al. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. JGastroenterol Hepatol 2007, 22:634-638.
101. Lee Y.M., Sutedja D., Wai C.T., et al. Arandomized controlled pilot study of pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008, 2:196-201.
102. ®) in treatment of patients with non-alcoholic steatohepatitis. Clin Perspect Gastroenterol Hepatol 2010, 1:3-10.
103. Gomez-Dominguez E., Gisbert J.P., Moreno-Monteagudo J.A., et al. Apilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006, 23:1643-1647.
104. Sreenivasa Baba C., Alexander G., Kalyani B., et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. JGastroenterol Hepatol 2006, 21(1 Pt 1):191-198.
105. Leuschner U.F., Lindenthal B., Herrmann G. High dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo controlled trial. Hepatology 2010, 52:472-479.
106. Lavin J.E. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. JPediatr 2000, 136:734-738.
107. Lavine J.E., Schwimmer J.B., Van Natta M.L., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305:1659-1668.
108. Madan K., Batra Y., Gupta D.S., et al. Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease. Indian J Gastroenterol 2005, 24:251-255.
109. Dunn W., Xu R., Schwimmer J.B. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008, 47:1947-1954.